These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

534 related items for PubMed ID: 9721864

  • 1. The role of hMLH1, hMSH3, and hMSH6 defects in cisplatin and oxaliplatin resistance: correlation with replicative bypass of platinum-DNA adducts.
    Vaisman A, Varchenko M, Umar A, Kunkel TA, Risinger JI, Barrett JC, Hamilton TC, Chaney SG.
    Cancer Res; 1998 Aug 15; 58(16):3579-85. PubMed ID: 9721864
    [Abstract] [Full Text] [Related]

  • 2. Human colon cancer cells surviving high doses of cisplatin or oxaliplatin in vitro are not defective in DNA mismatch repair proteins.
    Sergent C, Franco N, Chapusot C, Lizard-Nacol S, Isambert N, Correia M, Chauffert B.
    Cancer Chemother Pharmacol; 2002 Jun 15; 49(6):445-52. PubMed ID: 12107548
    [Abstract] [Full Text] [Related]

  • 3. Specificity of platinum-DNA adduct repair.
    Chaney SG, Vaisman A.
    J Inorg Biochem; 1999 Oct 15; 77(1-2):71-81. PubMed ID: 10626357
    [Abstract] [Full Text] [Related]

  • 4. Induction of JNK and c-Abl signalling by cisplatin and oxaliplatin in mismatch repair-proficient and -deficient cells.
    Nehmé A, Baskaran R, Nebel S, Fink D, Howell SB, Wang JY, Christen RD.
    Br J Cancer; 1999 Mar 15; 79(7-8):1104-10. PubMed ID: 10098743
    [Abstract] [Full Text] [Related]

  • 5. The role of DNA mismatch repair in platinum drug resistance.
    Fink D, Nebel S, Aebi S, Zheng H, Cenni B, Nehmé A, Christen RD, Howell SB.
    Cancer Res; 1996 Nov 01; 56(21):4881-6. PubMed ID: 8895738
    [Abstract] [Full Text] [Related]

  • 6. Resistance mechanisms following cisplatin and oxaliplatin treatment of the human teratocarcinoma cell line 2102EP.
    Rennicke A, Voigt W, Mueller T, Fruehauf A, Schmoll HJ, Beyer C, Dempke W.
    Anticancer Res; 2005 Nov 01; 25(2A):1147-55. PubMed ID: 15868958
    [Abstract] [Full Text] [Related]

  • 7. One-milliliter wet-digestion for inductively coupled plasma mass spectrometry (ICP-MS): determination of platinum-DNA adducts in cells treated with platinum(II) complexes.
    Yamada K, Kato N, Takagi A, Koi M, Hemmi H.
    Anal Bioanal Chem; 2005 Aug 01; 382(7):1702-7. PubMed ID: 15959768
    [Abstract] [Full Text] [Related]

  • 8. Enhanced replicative bypass of platinum-DNA adducts in cisplatin-resistant human ovarian carcinoma cell lines.
    Mamenta EL, Poma EE, Kaufmann WK, Delmastro DA, Grady HL, Chaney SG.
    Cancer Res; 1994 Jul 01; 54(13):3500-5. PubMed ID: 8012973
    [Abstract] [Full Text] [Related]

  • 9. Resistance to cytotoxic drugs in DNA mismatch repair-deficient cells.
    Aebi S, Fink D, Gordon R, Kim HK, Zheng H, Fink JL, Howell SB.
    Clin Cancer Res; 1997 Oct 01; 3(10):1763-7. PubMed ID: 9815561
    [Abstract] [Full Text] [Related]

  • 10. The cellular basis of the efficacy of the trinuclear platinum complex BBR 3464 against cisplatin-resistant cells.
    Perego P, Gatti L, Caserini C, Supino R, Colangelo D, Leone R, Spinelli S, Farrell N, Zunino F.
    J Inorg Biochem; 1999 Oct 01; 77(1-2):59-64. PubMed ID: 10626355
    [Abstract] [Full Text] [Related]

  • 11. hMLH1 expression and cellular responses of ovarian tumour cells to treatment with cytotoxic anticancer agents.
    Brown R, Hirst GL, Gallagher WM, McIlwrath AJ, Margison GP, van der Zee AG, Anthoney DA.
    Oncogene; 1997 Jul 03; 15(1):45-52. PubMed ID: 9233776
    [Abstract] [Full Text] [Related]

  • 12. Spontaneous development of drug resistance: mismatch repair and p53 defects in resistance to cisplatin in human tumor cells.
    Branch P, Masson M, Aquilina G, Bignami M, Karran P.
    Oncogene; 2000 Jun 29; 19(28):3138-45. PubMed ID: 10918568
    [Abstract] [Full Text] [Related]

  • 13. Modulation of drug resistance mediated by loss of mismatch repair by the DNA polymerase inhibitor aphidicolin.
    Moreland NJ, Illand M, Kim YT, Paul J, Brown R.
    Cancer Res; 1999 May 01; 59(9):2102-6. PubMed ID: 10232595
    [Abstract] [Full Text] [Related]

  • 14. Role of DNA replication in carrier-ligand-specific resistance to platinum compounds in L1210 cells.
    Gibbons GR, Kaufmann WK, Chaney SG.
    Carcinogenesis; 1991 Dec 01; 12(12):2253-7. PubMed ID: 1747924
    [Abstract] [Full Text] [Related]

  • 15. Loss of DNA mismatch repair in acquired resistance to cisplatin.
    Aebi S, Kurdi-Haidar B, Gordon R, Cenni B, Zheng H, Fink D, Christen RD, Boland CR, Koi M, Fishel R, Howell SB.
    Cancer Res; 1996 Jul 01; 56(13):3087-90. PubMed ID: 8674066
    [Abstract] [Full Text] [Related]

  • 16. Protein interactions with platinum-DNA adducts: from structure to function.
    Chaney SG, Campbell SL, Temple B, Bassett E, Wu Y, Faldu M.
    J Inorg Biochem; 2004 Oct 01; 98(10):1551-9. PubMed ID: 15458816
    [Abstract] [Full Text] [Related]

  • 17. Role of carrier ligand in platinum resistance of human carcinoma cell lines.
    Schmidt W, Chaney SG.
    Cancer Res; 1993 Feb 15; 53(4):799-805. PubMed ID: 8428361
    [Abstract] [Full Text] [Related]

  • 18. The role of DNA polymerase eta in translesion synthesis past platinum-DNA adducts in human fibroblasts.
    Bassett E, King NM, Bryant MF, Hector S, Pendyala L, Chaney SG, Cordeiro-Stone M.
    Cancer Res; 2004 Sep 15; 64(18):6469-75. PubMed ID: 15374956
    [Abstract] [Full Text] [Related]

  • 19. Loss of DNA mismatch repair facilitates reactivation of a reporter plasmid damaged by cisplatin.
    Cenni B, Kim HK, Bubley GJ, Aebi S, Fink D, Teicher BA, Howell SB, Christen RD.
    Br J Cancer; 1999 May 15; 80(5-6):699-704. PubMed ID: 10360646
    [Abstract] [Full Text] [Related]

  • 20. Effect of DNA polymerases and high mobility group protein 1 on the carrier ligand specificity for translesion synthesis past platinum-DNA adducts.
    Vaisman A, Lim SE, Patrick SM, Copeland WC, Hinkle DC, Turchi JJ, Chaney SG.
    Biochemistry; 1999 Aug 24; 38(34):11026-39. PubMed ID: 10460158
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.